Ratings, indices

Fitch Rating Agency confirmed Pfizer's rating at "A" level. The outlook is negative. The agency's analysts consider the company's debt burden high for the 'A' rating and expect the company to give preference to dividends, share buy-backs and acquisitions rather than debt repayment.